
Matt Fuller @MEPFuller
The answer is because our lawmakers refuse to step in and set price controls, preferring instead to respect drug patents that taxpayers — not pharmaceutical companies — paid to develop. — PolitiTweet.org
Public Citizen @Public_Citizen
.@AOC to Gilead CEO: The list price [for Truvada for PrEP] is almost $2,000 in the US. Why is it $8 in Australia? https://t.co/kPnMQSZE0G